Substantial savings opportunities exist by using lower-cost biologics for patients with plaque psoriasis, according to one ...

Studies involving multiple aspects of plaque psoriasis evolution, persistence, and progression have produced clues and ...

Clinical efficacy was evaluated using the Psoriasis Area and Severity Index (PASI), along with metabolic indicators such as ...

This came after the firm presented their proposal for the manufacturing and marketing of Roflumilast Cream 0.3% w/w for the ...

The hold, placed by the FDA on an early-stage clinical trial of an experimental BET inhibitor, stems from a recent ...

Fresenius Kabi, an operating company of Fresenius, announced today that the Centers for Medicare and Medicaid Services (CMS) issued a permanent, product-specific billing code for Otulfi® ...

The following is a summary of “Treatment of plaque psoriasis with guselkumab reduces systemic inflammatory burden as measured by neutrophil/lymphocyte ratio, platelet/lymphocyte ratio and ...

The U.S. Food and Drug Administration (FDA) on Friday verbally informed that it placed a clinical hold on VYNE Therapeutics ...

The European Commission (EC) has granted marketing authorisation for Johnson & Johnson's (J&J) Tremfya (guselkumab) to treat ...